What’s going on with legislation on ES cell research in Minnesota? I blogged before about how Oklahoma legislators were heading toward passing legislation that would make it a crime to do ES cell research. Unfortunately, that legislation just passed. As if that were not bad enough, now potentially life saving research in Minnesota is starting […]
Opponents of ES cell research launch stealth attack in Minnesota Read More »
How are things looking for the stem cell field for Spring 2011? Issue One. Getting to the clinic. At this point, Geron and ACT have their FDA-approved clinical trials underway using derivatives of human embryonic stem cells. As expected no news has leaked out on how things are going and it may well be Fall
Update on the stem cell field: Spring 2011 Read More »
A growing body of evidence has convincingly argued that iPS cells contain numerous abnormalities at the genetic and epigenetic levels. Often these changes have links to the machinery in cells that is responsible for cancer. As a result, many in the stem cell field have raised the notion that iPS cells may never be able
New papers support growing serious safety concerns about iPS cells Read More »
Each year brings more evidence that what causes many cancers is a case of biological betrayal on the part of stem cells via cancer stem cells. I have blogged before about the potential for stem cell-based regenerative medicine therapies to aid cancer patients. I have also written before about my own experiences as a cancer
Cancer Stem Cells: a new target Read More »
How is Geron doing along with other stem cell biotechs? What’s going on these days with biotech companies working on stem cell-based products? Geron and ACT Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they
Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »
It’s been more than 4 years since Shinya Yamanaka published the remarkable finding that his lab could transform or “reprogram” regular cells called fibroblasts into a very unique state that was quite similar to that of embryonic stem cells (ESC). Yamanaka called these new cells “iPS cells” for induced pluripotent stem cells. iPS cells Since
The Inside Scoop on iPS cells early in 2011 Read More »
What are recent trends in Stem Cell Research Funding? My post yesterday on the problems with the current system of stem cell funding generated a lot of interest from readers– more than a dozen left comments. Many of the comments were insightful even if readers disagreed on certain points. David Jensen also posted on an
Trends in Stem Cell Research Funding: where do we go from here? Read More »
Great ideas are the foundation of science, but funding makes great ideas become realities and a monopoly on funding hurts science. UPDATE: NIH data backs up our conclusions: overfunding wastes precious resources–give the money to smaller labs. Arguably the key driver of the exciting progress in stem cell research is funding. With the stakes so
Stem cell monopoly: do not pass go, do not collect $200,000 Read More »
Last Fall’s mid-term election brought into office several new Republican Governors who during their campaigns used strong, anti-embryonic stem (ES) cell research rhetoric. For example, then candidate for Governor of Wisconsin, Scott Walker (now the Governor) used some of the strongest language, which was ironic considering that human ES cells were first produced in Wisconsin
New Republican Governors Start Attack On Most Promising Stem Cell Research Read More »
What is Contagious cancer? Can one creature directly give another creature cancer? It appears so in dogs and that cancer is highly contagious. Contagious cancer When we think about transplants of cells, we think about hospitals and high-tech equipment used to give patients stem cells or other types of cells to help treat them for
Contagious cancer: the allograft your dog doesn’t want Read More »